Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
| ▸ | ZAP70 | P43403 | 6/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.77 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.73 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
| ▸ | BTK | Q06187 | 1/20 | 0.71 |
| ▸ | ITK | Q08881 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794822 | 1.00 | SYK (1.00) | SYKZAP70KCNH2AURKBCAMK1D | |
| SCHEMBL4714843 | 0.88 | SYK (0.78) | SYKZAP70KCNH2AURKBCAMK1D | |
| SCHEMBL2383949 | 0.87 | SYK (1.00) | SYKZAP70KCNH2AURKBCAMK1D | |
| SCHEMBL29794716 | 0.87 | SYK (1.00) | SYKZAP70KCNH2AURKBCAMK1D | |
| SCHEMBL4713443 | 0.86 | SYK (0.78) | SYKZAP70KCNH2AURKBCAMK1D | |
| Hydrochloric Acid SCHEMBL4711582 | 0.85 | SYK (0.76) | SYKZAP70KCNH2AURKBCAMK1D | |
| SCHEMBL1222899 | 0.84 | SYK (1.00) | SYKZAP70KCNH2AURKBCAMK1D | |
| SCHEMBL29794661 | 0.84 | SYK (1.00) | SYKZAP70KCNH2AURKBCAMK1D | |
| SCHEMBL4712719 | 0.83 | SYK (0.77) | SYKZAP70KCNH2AURKBCAMK1D | |
| SCHEMBL29794597 | 0.83 | SYK (0.77) | SYKZAP70KCNH2AURKBCAMK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013155381-A1 | TREATMENT FOR MICROBE-INDUCED INFLAMMATORY RESPONSES IN THE EYE | ALCON RESEARCH, LTD. (US) | 2013-10-17 | — | — | WO | claimed |
| US-20130274216-A1 | TREATMENT FOR MICROBE-INDUCED INFLAMMATORY RESPONSES IN THE EYE | ALCON RESEARCH, LTD. (US) | 2013-10-17 | — | — | US | claimed |
| EP-1054004-B1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | EP | claimed |
| US-20080139531-A1 | USE OF CONNECTIVE TISSUE MAST CELL STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPITHELIZATION AND WOUND REPAIR | ALCON MANUFACTURING LTD. (US) | 2008-06-12 | — | — | US | claimed |
| US-20080027034-A1 | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | NYCOMED GMBH (DE) | 2008-01-31 | — | — | US | claimed |
| EP-1796679-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | claimed |
| EP-1791538-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027378-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
| WO-2006027377-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
| US-6432963-B1 | ANTIINFLAMMATORY AGENTS; TYROSINE KINASE INHIBITOR | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | claimed |
| EP-1054004-A1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-11-22 | — | — | EP | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240158756-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-16 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| EP-1791538-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027378-A1 | ROFLUMILAST AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027377-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
| US-6432963-B1 | ANTIINFLAMMATORY AGENTS; TYROSINE KINASE INHIBITOR | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1054004-A1 | NOVEL PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027034-A1 | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | SYK, ZAP70, BTK | SYK 1/4885ZAP70 2/4885KCNH2 4123/4885 |
| US-20080139531-A1 | USE OF CONNECTIVE TISSUE MAST CELL STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPITHELIZATION AND WOUND REPAIR | CMA1, LTK, KIT | SYK 17/4885ZAP70 11/4885KCNH2 1134/4885 |
| US-20130274216-A1 | TREATMENT FOR MICROBE-INDUCED INFLAMMATORY RESPONSES IN THE EYE | SYK, MERTK, BTK | SYK 1/4885ZAP70 6/4885KCNH2 3644/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SYK 1558/4885ZAP70 3695/4885KCNH2 64/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | SYK 1558/4885ZAP70 3695/4885KCNH2 64/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | SYK 1864/4885ZAP70 3302/4885KCNH2 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.